A Must-Read Overview of the US Biotechnology Industry – Market Realist #pharmaceuticals #news


Posted On Aug 12 2017 by

#biotechnology industry

#

A Must-Read Overview of the US Biotechnology Industry

The above graph shows the breakdown of total revenues that biotechnology companies (IBB ) earn in the various disciplines. Biopharmaceuticals are drugs developed from biological sources and used to treat animal and human diseases. They account for about a third of total revenues, or $150 billion, earned by the biotechnology sector in 2014.

Biotech seeds, or genetically modified food, is the cross discipline between biotechnology and agriculture. Industrial biotechnology includes all other applications of biotechnology in sectors like chemicals, biofuels, feedstock, and energy.

Biopharmaceuticals

Biopharmaceutical companies such as Amgen (AMGN ), Biogen (BIIB ), Regeneron Pharmaceuticals (REGN ), and Celgene (CELG ) differ from pharmaceutical companies based on a drug’s development process. Traditionally, pharmaceutical companies have manufactured small molecule compounds that contain various chemicals. The drugs are termed “small molecule” since the molecule is small enough for the body to absorb its constituents in pill form.

Biopharmaceutical drug manufacturing involves programming live cells to produce large molecule drugs on a mass scale. The manufacturing process of biopharmaceutical drugs is more complex and capital-intensive than small molecule drugs. So these companies take longer than pharmaceutical companies to generate positive cash flows. Biopharmaceutical drugs have historically had higher commercial success rates than traditional pharmaceutical drugs.





Last Updated on: August 11th, 2017 at 11:50 pm, by


Written by admin


Leave a Reply

Your email address will not be published. Required fields are marked *